Author response to Colle et al.
Giovanni FucàFrancesca CortiFilippo PietrantonioPublished in: Journal for immunotherapy of cancer (2021)
The event of pseudoprogression is rare in patients with MSI-high metastatic colorectal cancer receiving immune checkpoint inhibitors. In this response to the Letter to the Editor by Colle et al, we highlight that the timing of disease re-assessment may influence the incidence of pseudoprogression, with early assessments being associated with higher incidence. Such dynamics should be considered when interpreting the efficacy of treatment.